TO
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Health-related quality of life in trials with high rates of early censoring : Caution advised | European journal of cancer |  | 2024 | 18 | 17 | ||
| Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review | Journal of thoracic oncology | | 2024 | 32 | 90 | ||
| Equal censoring but still informative : When the reasons for censoring differ between treatment arms | European journal of cancer | | 2024 | 21 | 14 | ||
| Interpréter un essai randomisé en oncologie : éléments clés en clinique | Revue médicale suisse |  | 2024 | 29 | 0 | ||
| Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials | European journal of cancer | | 2024 | 26 | 15 | ||
| A novel framework to assess haematology and oncology registration trials : The THEOREMM project | European journal of clinical investigation | | 2024 | 23 | 18 | ||
| Neoadjuvant followed by adjuvant pembrolizumab in melanoma : time biases in the data analysis of the SWOG S1801 trial | Translational oncology | | 2024 | 23 | 20 | ||
| CDK4/6 inhibitors as adjuvant therapy in early breast cancer ? Uncertain benefits, guaranteed harms | European journal of cancer | | 2024 | 26 | 25 | ||
| Qualitative assessment of the control arm in oncology randomized clinical trials | | 2024 | 110 | 138 | |||
| Eligibility for human leukocyte antigen-based therapeutics by race and ethnicity | JAMA network open | | 2023 | 21 | 4 | ||
| Cost of drug wastage from dose modification and discontinuation of oral anticancer drugs | JAMA oncology | | 2023 | 20 | 4 | ||
| Voyage de nuit | Revue médicale suisse | | 2023 | 55 | 3 | ||
| Quality of life in the adjuvant setting : a meta-analysis of us food and drug administration approved anti-cancer drugs from 2018 to 2022 | Journal of cancer policy | | 2023 | 17 | 8 | ||
| Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer | BMC medicine | | 2023 | 28 | 18 | ||
| The definition of long COVID used in interventional studies | European journal of clinical investigation | | 2023 | 16 | 0 | ||
| Cancer drug price and novelty in mechanism of action | JAMA network open | | 2023 | 79 | 20 | ||
| Molecular testing to deliver personalized chemotherapy recommendations : risking over and undertreatment | BMC medicine | | 2022 | 20 | 14 | ||
| The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy | European journal of cancer | | 2021 | 52 | 0 | ||
| Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? | Cancer treatment reviews | | 2021 | 34 | 19 | ||
| Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer | Clinical Cancer Research | | 2018 | 455 | 1 | ||
| Ipilimumab-related hypophysitis may precede severe CNS immune attack | Annals of Oncology | | 2016 | 432 | 0 |
